x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243281
| Product Information | |
|---|---|
| CAS No. | 1303470-48-5 |
| Formula | C21H27ClN8S |
| Molecular Weight | 459.01 |
| SMILES | [H]Cl.CSC(C=CC=C1)=C1NC2=NC(N3CCNCC3)=NC4=C2N=CN=C4NCC5CC5 |
| Target | Ketohexokinase |
| Product Description | KHK-IN-1 hydrochloride (compound 8) is a selective and cell membrane permeable ketohexokinase (KHK) inhibitor (IC50=12 nM; F=34%). KHK-IN-1 hydrochloride inhibits the production of F1P in HepG2 cell lysates (IC>sub>50=400 nM). KHK-IN-1 hydrochloride has potential for the study of diabetes and obesity. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | Light yellow to yellow |
| Purity | 98.05% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
